
Novel Malaria Treatment Shows Positive Results for Infants <5kg: Novartis & Medicines for Malaria Venture
Novartis and Medicines for Malaria Venture (MMV) have unveiled encouraging results from their phase II/III CALINA trial, indicating that a newly formulated version of Coartem® (artemether-lumefantrine) tailored for infants weighing under 5kg with malaria demonstrates the necessary pharmacokinetic profile, along…












